Security
Milestone Pharmaceuticals Inc. Common Shares · MIST
MISTNASDAQCommon stockCurrentCIK 1408443Updated Oct 29, 2026
MIST price & chart
Loading TradingView…
NASDAQ:MIST on TradingView ↗About the company
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib-RVR. https://milestonepharma.com/
In the news
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026 ↗
Recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Other Events
Items 8.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
SCHEDULE 13G - filed by Pavaki Capital Management LLC regarding Milestone Pharmaceuticals Inc.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 87,750,000Source | 82,706,000Source | 181,625,000Source | 47,417,000Source | 89,232,000Source | 193,734,000Source | 61,885,000Source | 96,001,000Source | 113,561,000Source | 75,499,000Source | 75,226,000Source | 74,483,000Source |
| Property, Plant and Equipment, NetUSD | 136,000Source | 201,000Source | 469,000Source | 159,000Source | 222,000Source | 500,000Source | 176,000Source | 249,000Source | 511,000Source | 197,000Source | 277,000Source | 257,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 46,685,000Source | 12,799,000Source | 169,728,000Source | 42,499,000Source | 13,262,000Source | 71,317,000Source | 45,085,000Source | 10,131,000Source | 73,046,000Source | 25,314,000Source | 13,760,000Source | 7,636,000Source |
| Inventory, NetUSD | — | — | 4,722,000Source | — | — | 1,826,000Source | — | — | 648,000Source | — | — | — |
| Assets, CurrentUSD | 86,670,000Source | 80,990,000Source | 180,327,000Source | 46,168,000Source | 87,359,000Source | 192,253,000Source | 60,475,000Source | 93,967,000Source | 111,921,000Source | 73,926,000Source | 73,032,000Source | 71,803,000Source |
| Operating Lease, Right-of-Use AssetUSD | 944,000Source | 1,515,000Source | 829,000Source | 1,090,000Source | 1,651,000Source | 981,000Source | 1,234,000Source | 1,785,000Source | 1,129,000Source | 1,376,000Source | 1,917,000Source | 2,423,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 67,249,000Source | 58,694,000Source | 163,407,000Source | 65,162,000Source | 57,254,000Source | 157,685,000Source | 68,008,000Source | 56,080,000Source | 71,792,000Source | 62,352,000Source | 58,455,000Source | 8,135,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 311,776,000Source | 288,006,000Source | 384,985,000Source | 288,263,000Source | 287,932,000Source | 373,702,000Source | 288,188,000Source | 287,879,000Source | 352,619,000Source | 288,048,000Source | 260,504,000Source | 273,900,000Source |
| Additional Paid in CapitalUSD | 66,270,000Source | 38,112,000Source | 62,867,000Source | 42,188,000Source | 36,713,000Source | 63,367,000Source | 40,919,000Source | 35,346,000Source | 64,104,000Source | 39,568,000Source | 33,834,000Source | 24,437,000Source |
| Retained Earnings (Accumulated Deficit)USD | -413,194,000Source | -355,182,000Source | -485,283,000Source | -401,272,000Source | -345,743,000Source | -456,669,000Source | -388,306,000Source | -336,380,000Source | -430,603,000Source | -367,545,000Source | -326,026,000Source | -266,341,000Source |
| Stockholders' Equity Attributable to ParentUSD | 20,501,000Source | 24,012,000Source | 18,218,000Source | -17,745,000Source | 31,978,000Source | 36,049,000Source | -6,123,000Source | 39,921,000Source | 41,769,000Source | 13,147,000Source | 16,771,000Source | 66,348,000Source |
| Liabilities and EquityUSD | 87,750,000Source | 82,706,000Source | 181,625,000Source | 47,417,000Source | 89,232,000Source | 193,734,000Source | 61,885,000Source | 96,001,000Source | 113,561,000Source | 75,499,000Source | 75,226,000Source | 74,483,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 10,524,000Source | 5,258,000Source | 22,184,000Source | 9,283,000Source | 4,567,000Source | 20,944,000Source | 12,963,000Source | 4,130,000Source | 13,979,000Source | 8,126,000Source | 7,226,000Source | 6,139,000Source |
| Operating Lease, Liability, CurrentUSD | 483,000Source | 582,000Source | 670,000Source | 515,000Source | 567,000Source | 659,000Source | 542,000Source | 555,000Source | 647,000Source | 571,000Source | 546,000Source | 495,000Source |
| Operating Lease, Liability, NoncurrentUSD | 519,000Source | 1,002,000Source | 192,000Source | 641,000Source | 1,156,000Source | 366,000Source | 758,000Source | 1,306,000Source | 539,000Source | 874,000Source | 1,457,000Source | 1,996,000Source |
| Other Liabilities, NoncurrentUSD | — | — | 61,000Source | — | — | 72,000Source | — | — | 83,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 82,600,000Source | 76,400,000Source | 170,600,000Source | 43,400,000Source | 83,300,000Source | 184,200,000Source | 56,000,000Source | 89,500,000Source | 106,000,000Source | 69,700,000Source | 66,000,000Source | 64,500,000Source |
| Long-term DebtUSD | 56,206,000Source | 52,434,000Source | 59,207,000Source | 55,238,000Source | 51,531,000Source | 58,192,000Source | 54,287,000Source | 50,644,000Source | 57,191,000Source | 53,352,000Source | 49,772,000Source | — |
| Short-term InvestmentsUSD | 35,900,000Source | 63,620,000Source | 881,000Source | 918,000Source | 69,991,000Source | 112,899,000Source | 10,873,000Source | 79,350,000Source | 32,914,000Source | 44,381,000Source | 52,243,000Source | 56,949,000Source |
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Accounts Payable, Current | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Accrued Liabilities, Current | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Deferred Revenue, Current | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -26,066,000Source | -20,761,000Source | -63,058,000Source | -41,519,000Source | -59,685,000Source | -58,388,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 56,000Source | 27,000Source | 114,000Source | 105,000Source | 92,000Source | 89,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,282,000Source | 1,351,000Source | 7,461,000Source | 5,776,000Source | 9,534,000Source | 9,048,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 1,178,000Source | — | 648,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -16,053,000Source | -13,952,000Source | -49,041,000Source | -28,848,000Source | -46,424,000Source | -52,469,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -80,030,000Source | 33,583,000Source | 11,246,000Source | 8,283,000Source | 4,756,000Source | -57,124,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 45,000Source | 6,000Source | 302,000Source | 33,000Source | 112,000Source | 272,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 94,354,000Source | 140,000Source | 85,527,000Source | 32,119,000Source | 47,792,000Source | 3,088,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -1,729,000Source | 19,771,000Source | 47,732,000Source | 11,554,000Source | 6,124,000Source | -106,505,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,250,000Source | 1,399,000Source | 1,338,000Source | 1,308,000Source | 1,282,000Source | 1,351,000Source | 7,461,000Source | 5,776,000Source | 9,534,000Source | 9,048,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 117,000Source | 102,000Source | 432,000Source | 370,000Source | 244,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 82,600,000Source | 76,400,000Source | 170,600,000Source | 43,400,000Source | 184,200,000Source | 56,000,000Source | 106,000,000Source | 69,700,000Source | 66,000,000Source | 64,500,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 114,000Source | 105,000Source | 92,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | -8,000Source | — | -141,000Source |
| General and Administrative ExpenseUSD | — | — | 3,263,000Source | 3,742,000Source | — | 3,759,000Source | 4,824,000Source | 5,167,000Source | 17,274,000Source | 16,742,000Source | 15,932,000Source | 15,718,000Source |
| InterestExpenseNonoperatingUSD | — | — | 967,000Source | 903,000Source | 4,725,000Source | 951,000Source | 4,135,000Source | 935,000Source | 3,838,000Source | 3,581,000Source | — | — |
| Investment Income, InterestUSD | — | — | 874,000Source | 1,080,000Source | 1,741,000Source | 516,000Source | 1,732,000Source | 697,000Source | 2,920,000Source | 4,164,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,922,000Source | -9,439,000Source | -28,614,000Source | -12,966,000Source | -26,066,000Source | -20,761,000Source | -63,058,000Source | -41,519,000Source | -59,685,000Source | -58,388,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 668,000Source | 697,000Source | 681,000Source | 490,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 10,890,000Source | — | 37,593,000Source | 27,258,000Source | — | 2,630,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 444,000Source | 53,000Source | 189,000Source | 420,000Source |
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Increase (Decrease) in Accounts Payable | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -11,829,000Source | -9,616,000Source | -25,630,000Source | -12,531,000Source | -23,663,000Source | -20,523,000Source | -62,140,000Source | -42,102,000Source | -61,098,000Source | -59,642,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -63,058,000Source | -41,519,000Source | -59,685,000Source | -58,388,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,922,000Source | -9,439,000Source | -28,614,000Source | -12,966,000Source | -26,066,000Source | -20,761,000Source | -63,058,000Source | -41,519,000Source | -59,685,000Source | -58,388,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.12Source | -0.14Source | -0.21Source | -0.2Source | -0.2Source | -0.31Source | -0.75Source | -0.67Source | -1.39Source | -1.38Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.12Source | -0.14Source | -0.21Source | -0.2Source | -0.2Source | -0.31Source | -0.75Source | -0.67Source | -1.39Source | — |
| Interest Expense (non-operating)USD | — | — | 967,000Source | 903,000Source | 4,725,000Source | 951,000Source | 4,135,000Source | 935,000Source | 3,838,000Source | 3,581,000Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 3,263,000Source | 3,742,000Source | — | 3,759,000Source | 4,824,000Source | 5,167,000Source | 17,274,000Source | 16,742,000Source | 15,932,000Source | 15,718,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 2,554,000Source | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | — | — | — | — | — | — | 3,967,000Source | 1,254,000Source |
| Investment Income, InterestUSD | — | — | 874,000Source | 1,080,000Source | 1,741,000Source | 516,000Source | 1,732,000Source | 697,000Source | 2,920,000Source | 4,164,000Source | — | — |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 668,000Source | 697,000Source | 681,000Source | 490,000Source |
| Research and Development ExpenseUSD | — | — | 3,940,000Source | 3,963,000Source | 3,509,000Source | 3,669,000Source | 3,251,000Source | 4,978,000Source | 18,108,000Source | 14,357,000Source | 31,052,000Source | 39,829,000Source |
| Total Revenue | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Cost of Revenue | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Selling, General and Administrative Expense | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Costs and Expenses | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-295860
Filing attachments
tm2624766d1_ex99-1.htm · 8-K · 2026-09-03
Exhibit 99.1 Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT Approval Triggers $2.0 Million Payment to Milestone Pharmaceuticals MONTREAL and CHARLOTTE, N.C., - September 3, 2026 - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a bi…
Read attachment ↗tm2614433d1_ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 tm2614433d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray Phase 3 registrational trial of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR) first clinical sites activated, advancing Milestone’s potential, sec…
Read attachment ↗tm2614252d2_ex4-3.htm · S-3 · 2026-05-13
Exhibit 4.3 Milestone Pharmaceuticals Inc., Iss u er AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20__ Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 …
Read attachment ↗tm2614252d2_ex4-5.htm · S-3 · 2026-05-13
Exhibit 4.5 Milestone Pharmaceuticals Inc. and , As Warrant Agent Form of Common Share Warrant Agreement Dated As Of Milestone Pharmaceuticals Inc. Form of Common Share Warrant Agreement This Common Share Warrant Agreement (this “Agreement”), dated as of [●], between MILESTONE PHARMACEUTICALS INC., a corporation existing under the laws of the province of Québec (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having …
Read attachment ↗tm2614252d2_ex4-6.htm · S-3 · 2026-05-13
Exhibit 4.6 Milestone Pharmaceuticals Inc. and _____________, As Warrant Agent Form of Preferred Share Warrant Agreement Dated As Of __________ Milestone Pharmaceuticals Inc. Form of Preferred Share Warrant Agreement This Preferred Share Warrant Agreement (this “Agreement”), dated as of [●], between Milestone Pharmaceuticals Inc., a corporation existing under the laws of the province of Québec (the “Company”), and [●], a [corporation] [national banking association] organized and existing …
Read attachment ↗tm2614252d2_ex4-7.htm · S-3 · 2026-05-13
Exhibit 4.7 Milestone Pharmaceuticals Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of __________ Milestone Pharmaceuticals Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Milestone Pharmaceuticals Inc., a corporation organized under the laws of the province of Québec (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the la…
Read attachment ↗